

Savella® (milnacipran)
Effective 11/26/2018

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Exceptions	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029

Overview

Savella® is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia.

Coverage Guidelines

Authorization may be granted for members with a diagnosis of fibromyalgia who has been started and stabilized on Savella for at least 30 days excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when ALL the following criteria are met:

1. Member has a diagnosis of fibromyalgia
2. Member has had a documented side effect, allergy, or treatment failure with an SNRI such as a generic venlafaxine product (Effexor® XR caps/tabs, etc.), duloxetine (Cymbalta®), or a desvenlafaxine product [Pristiq®, Khedezla®, etc.].
3. Member has had a documented side effect, allergy, or treatment failure with at least one agent from two different categories including:
 - a. Tricyclic antidepressants (e.g., amitriptyline, doxepin, desipramine, imipramine, etc.)
 - b. SSRI's (e.g., citalopram, fluoxetine, paroxetine, sertraline, etc.)
 - c. Cyclobenzaprine
 - d. Gabapentin

Limitations

1. Initial approvals will be granted for 36 months.
2. The following quantity limits apply:

Savella Titration pack	One time only
------------------------	---------------

Savella tablets	60 tablets per 30 days
-----------------	------------------------

References

1. Clauw DJ., Mease P., Palmer RH., Gendreau RM., Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. *Clinical Therapeutics*. 2008; 30(11):1988-2004.
2. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. *J Rheumatol*. 2009; 36:398-409.
3. Peterson EL. Fibromyalgia--management of a misunderstood disorder. *J Am Acad Nurse Pract*. 2007 Jul;19(7):341-8.
4. Chakrabarty S, Zoorob R. Fibromyalgia. *Am Fam Physician*. 2007 Jul 15;76(2):247-54.
5. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. *JAMA*.2004; 292(19):2388-2395.
6. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence- based recommendations for the management of fibromyalgia syndrome. *Ann Rheum Dis*. 2008; 67:536-541.
7. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. *Hum Psychopharmacol Clin Exp*. 2004; 19: S27-S35.
8. Savella (milnacipran) [prescribing information]. Irvine, CA: Allergan USA Inc; December 2017
9. Buckhardt CS et al. Guideline for the management of fibromyalgia syndrome pain in adults and children. Glenview (IL): American Pain Society (APS); 2005. 109p (Clinical practice guideline; no. 4).
10. Traynor LM, Thiessen CN, Traynor AP. Pharmacotherapy of fibromyalgia. *Am J Health-Syst Pharm*. 2011;68(July 15, 2011):1307-1319.
11. Arnold LM, Palmer RH, Ma Y. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. *Clinical Journal of Pain*. 2013;29(12):1021-8.
12. Sumpton JE, Moulin DE. Fibromyalgia. *Handbook of Clinical Neurology*. 2014; 119:513-27.

Review History

11/22/2010 – Reviewed
11/28/2011 – Reviewed and updated
11/26/2012 – Reviewed
11/25/2013 – Reviewed and updated
08/04/2014 – Updated (duloxetine generic; 12/30/2013 file)
11/24/2014 – Reviewed and updated in P&T Meeting
11/27/2017 – Reviewed
11/26/2018 – Reviewed in P&T Meeting
01/22/2019 – Reviewed
01/22/2020 – Reviewed at P&T.

